Nation’s Largest Generic Drug Maker to Pay $450 Million to Resolve Kickback, Price-Fixing Claims

Teva Pharmaceuticals settles kickback and price-fixing allegations involving Medicare copays and drug price collusion.

The logo of Teva Pharmaceutical Industries in Tel Aviv, Israel, on Feb. 19, 2019. Amir Cohen/Reuters

Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. (collectively, Teva) have agreed to pay $450 million to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), according to the U.S. Department of Justice (DOJ).

Teva is an Israeli company, with U.S. headquarters in Parsippany, New Jersey, and is the largest generic drug manufacturer in the United States, according to the DOJ.